Assays & Animal Models - Outline of research priorities related to the Omicron variant

Overview

Background

The WHO R&D Blueprint Working Groups on COVID-19 Assays and Animal Models met on 29 November 2021 to discuss action plans and current knowledge about the emerging SARS-CoV-2 Omicron variant of concern first identified in the South Africa Gauteng province. 

Due to the presence of multiple mutations in the SARS-CoV-2 spike protein, there is an urgent need to evaluate the cross reactivity, transmissibility, and pathogenicity of the omicron VOC. The WHO working groups met to discuss the following specific objectives:

• Identify the knowledge gaps and key research priorities
• Identify any participating experts with access to omicron isolates and/or sequences. Establish mechanisms for rapid sharing of viruses and reagents.
• Discuss any existing data or plans to test omicron variant antibody neutralization
• Discuss and setup transmissibility experiments
• Discuss any data or plans to test omicron variant interferon antagonism
• Discuss plans to test infectivity and pathogenesis in animal models